INT230-6 + ipilimumab

**INT230-6 + ipilimumab** is a combination therapy under investigation for various advanced solid tumors, especially relapsed, refractory, and metastatic sarcomas. INT230-6 is an investigational, intratumorally injected formulation composed of two cytotoxic agents—cisplatin and vinblastine—co-formulated with the penetration enhancer SHAO, designed to facilitate drug dispersion and penetration into tumor tissue. The direct tumor injection leads to rapid tumor necrosis, antigen release, and strong local immune activation. Combining INT230-6 with ipilimumab, an anti-CTLA-4 monoclonal antibody that promotes T-cell activation by blocking an immune checkpoint, aims to further boost systemic antitumor immunity. The combination is intended to provide direct cytotoxic effects and enhanced immune-mediated tumor eradication, even in traditionally immunotherapy-resistant cancers such as sarcoma. INT230-6 is being developed by Intensity Therapeutics; ipilimumab is developed and marketed by Bristol Myers Squibb[1][2][3][5].

Other names

INT230-6 and ipilimumabINT-230-6 and ipilimumabINT 230-6 and ipilimumab